| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Stimulants, or sympathomimetic amines, increase central nervous system activity and can be used to treat and manage attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. While some stimulants have pharmacological applications, others are categorized as Scheduled I compounds by the Drug Enforcement Agency and are often sold illicitly and abused. As a result, many professional practice guidelines recommend compliance testing in patients prescribed stimulant medications.
16 million
16 million adults use prescription stimulants in the United States annually1
5.1 million
5.1 million people misused prescription stimulants in 20182
50%
50% reduction in substance misuse when combining clinical urine drug tests with other risk-mitigation strategies3
Stimulant test menu
Our targeted, high-resolution mass spectrometry screening panel identifies and confirms the presence of 10 stimulants and phencyclidine (PCP) with a single test. Utilizing mass spectrometry in place of traditional immunoassay testing not only increases specificity, but eliminates false positives caused by cross-reactivity with other medications. By reducing the need for additional confirmatory testing, the targeted stimulant screen saves time and money while enabling clinicians to accurately detect stimulant use and monitor compliance.
Key testing
Several of our comprehensive profiles include targeted stimulant screening (Mayo ID: TSTIM).
Panel testing
Key testing